human relaxin-2 sulfoxide

Human relaxin-2 sulfoxide is a synthetic peptide analog of the endogenous human relaxin-2 hormone, characterized by the specific oxidation of the methionine residue (typically at position B25) to a sulfoxide group. Developed by Relaxera, this modified peptide acts as an agonist of the Relaxin Family Peptide Receptor 1 (RXFP1). Relaxin-2 signaling is associated with significant cardiovascular and anti-fibrotic benefits, including systemic and renal vasodilation, inhibition of collagen synthesis, and anti-inflammatory effects. While sulfoxidation can occur as a natural degradation product under oxidative stress, specific synthetic versions are utilized in preclinical research to study the impact of methionine oxidation on relaxin's pharmacological profile and as potential therapeutic candidates for heart failure and fibrotic disorders. It is currently in the preclinical stage of development.

Other names

Met(O)25-relaxin-2oxidized human relaxin-2